Loading patent…
AssigneesAmgen Research (Munich) GmbH, Amgen Inc.
InventorsGerhard Zugmaier, Peter Kufer, Shilpa Alekar
Estimating the term…
The present invention relates to a method for risk-stratifying subjects suffering from B-precursor acute lymphoblastic leukemia (ALL), wherein said subjects are intended for a therapy comprising administration of a CD3 binding domain. Risk-stratification is based on the determination of the amount blast cells in a bone marrow sample from said subject, and/or on the determination of the number of blast cells per 1 μl in a CSF sample from said subject. According to the category into which subjects are risk-stratified, said subjects can be appropriately treated, while their risk of a potential adverse neurological reaction can be reduced or even excluded.
A method of treating B-precursor acute lymphoblastic leukemia (ALL) in a subject determined to be at a reduced risk for developing a potential adverse neurological reaction from a therapy which comprises re-directing of T-cells against target cells, comprising selecting said subject for having a reduced risk when the subject has been determined as having
Dependencies are inferred from the claim text.